Kinea Bio is a patient-focused biotechnology startup that aims to speed the development of next-generation AAV-based gene treatments.
Kinea Bio has raised $1.1M in total funding. The most recent round was Grant. The last funding was announced in September 2025.
Kinea Bio's investors include Jain Foundation, Parent Project Muscular Dystrophy.
Kinea Bio is headquartered in Seattle, United States.
Kinea Bio is a patient-focused biotechnology startup that aims to speed the development of next-generation AAV-based gene treatments.
Kinea Bio is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Kinea Bio — Funding & Investors." VCBacked, September 23, 2025, https://www.vcbacked.co/company/kinea-bio. Accessed August 13, 2026.
VCBacked. (2025). Kinea Bio — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/kinea-bio
{{cite web |title=Kinea Bio — Funding & Investors |url=https://www.vcbacked.co/company/kinea-bio |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated